Skip to main content

ADVERTISEMENT

Poster

This study explores the influence of race and sexual orientation on the stigma surrounding the treatment of GAD and MDD in a cohort of college students.
10/26/2023
START is an ongoing, noninterventional, prospective, single-arm, 2-cohort (tardive dyskinesia [TD] and Huntington disease) study evaluating dosing and treatment patterns with deutetrabena...
10/26/2023
An updated claims database analysis of two formulations of the LAI aripiprazole, to evaluate the benefit of different dosing intervals to optimize the annual drug treatment costs among pa...
10/26/2023
Valbenazine and deutetrabenazine product labeling both recommend dose adjustment for and/or avoidance of certain concomitant medications because of potential for drug–drug interactions (D...
10/26/2023
Use of long-acting injectable antipsychotics (LAIs) for treatment of bipolar I disorder (BP-I) is limited to the severest cases, despite evidence showing their potential in treating early...
10/26/2023
69 patients were grouped based on their baseline individual alpha frequency (IAF): 8, 9, 10, or 11 Hz. We show the percentage of patients in each group that reported a decrease, increase,...
10/26/2023
Diagnostic determination for PTSD is often deduced through clinical interview and/or self-reported assessment tools including the PCL-5. Given the weighted subjectivity of current methods...
10/26/2023
Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a novel long-acting injectable formulation of aripiprazole monohydrate for gluteal intramuscular administration once every 2 months. A pre...
10/26/2023
Idiopathic hypersomnia (IH) is a rare neurologic disorder characterized by excessive daytime sleepiness, sleep inertia, long and unrefreshing sleep/naps, and cognitive dysfunction. Sympho...
10/26/2023
This study used qualitative interviews to understand the patient experience of narcolepsy (types 1[NT1]=12 and 2 [NT2]=10). Many participants received a narcolepsy diagnosis at least 10 y...
10/26/2023